Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of...
110 insider purchases on record · latest filing 2025-06-23.
Insiders have also filed 35 sale transactions at SVRA.